IL6 and neoplasm: We posit that the ERO1α/IL-6/STAT3/SLC7A11 pathway is critical for mTORC1-mediated ferroptosis resistance and tumor growth and that it can be targeted for the treatment of cancers associated with dysregulated mTORC1 signaling.